Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Down 0.1% in January: Crecon Report
March 10, 2015
- 74 Drug Makers Paid 483.1 Billion Yen to Healthcare Providers in FY2013: Jiho Tally
March 9, 2015
- Meiji Seika Pharma Commences PIII Study of Ziprasidone in Japan
March 9, 2015
- RaQualia, Nagoya Univ. Enter Joint Research Agreement for DNA Polymerase Eta Inhibitors
March 9, 2015
- US Merck, Eisai to Jointly Develop Combination Therapy of Anti-PD-1 Therapy with Anticancer Agents in US
March 9, 2015
- Eisai Aims at 120 Billion Yen Sales for Lenvima: CEO Naito
March 6, 2015
- MSD Japan Sales Down 14%, Januvia Sags 6.7%
March 6, 2015
- Kyowa Kirin Initiates PII Study of Bardoxolone Methyl in Japan
March 6, 2015
- Opdivo Approved for Lung Cancer in US
March 6, 2015
- Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
- Merck Japan Names Ralf Annasentz as New President
March 5, 2015
- Sanwa Kagaku to Promote Katsumi Hata as New President
March 5, 2015
- Toray Files Remitch Capsules for Pruritus in Chronic Liver Disease
March 5, 2015
- GSK, Novartis Unveil Details of 3-Part Asset Swap Deal in Japan
March 4, 2015
- Weber to Become CEO of Takeda in April
March 4, 2015
- Announcement: 12th Annual BIO Asia International Conference to Be Held on March 24, 25
March 4, 2015
- Japan Units of Abbott, Mylan to Run Separate Operations for Now
March 4, 2015
- Almac Aims to Expand Japan Business
March 4, 2015
- Santen Files Sirolimus for Noninfectious Uveitis in Europe
March 4, 2015
- Chugai, Athersys Join Hands for Cell Therapy Treatment
March 4, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…